Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal International Journal of Cell and Biomedical Science Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)
Dewayanti, Farahana Kresno
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Aminolevulinic Acid Dehydratase Allelic Frequency and Lead Toxicity in Children Under-Five in a Former Used Lead-Acid Battery Area Irawati, Yana; Kusnoputranto, Haryoto; Achmadi, Umar Fahmi; Safrudin, Ahmad; Sitorus, Alfred; Risandi, Rifqi; Wangsamuda, Suradi; Permana, Dendi Hadi; Syahrani, Lepa; Dewayanti, Farahana Kresno; Asih, Puji B S; Syafruddin, Din
Kesmas Vol. 17, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Polymorphisms in the Aminolevulinic Acid Dehydratase (ALAD) gene responsible for the ALAD1 and ALAD2 alleles have been implicated in susceptibility to lead toxicity. This study aimed to determine the allelic frequency of ALAD2 among children living in Bogor District, Indonesia, and its association with blood lead levels (BLLs) and lead toxicity. A cross-sectional study involving 128 children was conducted during September-October 2019 in the former ULAB area in Cinangka Village. The ALAD polymorphism, BLLs, and hematological parameters were evaluated. Blood samples were taken for dried blood spotting on filter paper, blood film, and BLL measurement. The PCR amplification and sequencing of the genomic DNA revealed the presence of two forms of the ALAD2 allele: 177C and 177T with a frequency of 0.05. Analysis of the correlation between the ALAD2 allele, BLLs, and basophilic stippling revealed that ALAD2 carriers had a five times higher risk of high BLLs, (OR = 5.359, p-value = 0.155) and had a slightly higher risk of exhibiting basophilic stippling (OR = 1.09, p-value = 1.000). Although not statistically significant, these findings suggested that the ALAD genotype may modify BLLs and lead to toxicity. The ALAD2 allele(177T) is firstly reported in any population in the world.
The Role of Mesenchymal Stem Cell Secretome and Extracellular Vesicles in Targeting Emerging and Persistent Viral Reservoirs Beyond Respiratory Viruses: A Narrative Review Amalina, Nur Dina; Sitompul, Faya Nuralda; Febri, Ririn Rahmala; Dewayanti, Farahana Kresno; Rafidah, Izzati; Wargadipura, Fitri Hasnaulia
International Journal of Cell and Biomedical Science Vol 4 No 12 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i12.81

Abstract

Background: Persistent viral infections remain a significant global health challenge, with viral reservoirs in anatomically and immunologically privileged sites evading conventional therapeutic approaches. Mesenchymal stem cells (MSCs) and their secreted factors, including the secretome and extracellular vesicles (EVs), have emerged as promising therapeutic modalities due to their immunomodulatory, anti-inflammatory, and tissue-regenerative properties. Objective: This narrative review synthesizes current evidence on the therapeutic potential of MSC-derived secretome and EVs in targeting viral reservoirs beyond respiratory infections, including human immunodeficiency virus (HIV), hepatitis viruses, herpesviruses, and emerging arboviruses. Methods: A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science databases for studies published between 2015 and 2025, focusing on MSC secretome, extracellular vesicles, viral reservoirs, and persistent viral infections. Results: MSC secretome and EVs demonstrate multifaceted antiviral mechanisms including direct viral inhibition, immunomodulation of host responses, tissue repair of virus-induced damage, and potential targeting of latent viral reservoirs. Evidence from in vitro, animal models, and limited clinical studies suggests efficacy against HIV latent reservoirs, chronic hepatitis B and C infections, cytomegalovirus reactivation, and dengue-induced pathology. Key bioactive components include microRNAs, cytokines, growth factors, and antimicrobial peptides that collectively modulate viral replication and host immunity. Conclusion: MSC-derived therapeutics represent a novel approach to addressing persistent viral infections, although significant challenges remain in standardization, scalability, delivery methods, and clinical translation. Future research should focus on optimizing EV production, identifying specific bioactive components, elucidating the mechanisms of reservoir penetration, and conducting rigorous clinical trials to establish the efficacy and safety profiles of these products.
Co-Authors Ahmad Safrudin Amalina, Nur Dina Asih, Puji B S Din Syafruddin Febri, Ririn Rahmala Haryoto Kusnoputranto Irawati, Yana Permana, Dendi Hadi Rafidah, Izzati Risandi, Rifqi Sitompul, Faya Nuralda Sitorus, Alfred Syahrani, Lepa Umar Fahmi Achmadi Wangsamuda, Suradi Wargadipura, Fitri Hasnaulia